Melanin-concentrating hormone (MCH) receptor antagonists are disclosed having utility for the treatment of MCH receptor-based disorders such as obesity. The compounds of this invention have the following structure: ##STR00001## including stereoisomers and pharmaceutically acceptable salts thereof, wherein n, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, and R.sub.6 are as defined herein. Pharmaceutical compositions containing a compound of this invention, as well as methods relating to the use thereof, are also disclosed.